Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 24, 2024 07:35 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Present at MST Financial Webinar

MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
July 17, 2024 07:35 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers...
July 17, 2024 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated...
June 12, 2024 19:22 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar

MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
May 29, 2024 19:21 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May ...
May 08, 2024 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) --...
April 30, 2024 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson’s...
April 29, 2024 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia

– New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:...
April 17, 2024 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...
April 10, 2024 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...